首页> 外文期刊>Regulatory peptides. >The effect of Glucagon-Like Peptide-2 on mesenteric blood flow and cardiac parameters in end-jejunostomy short bowel patients.
【24h】

The effect of Glucagon-Like Peptide-2 on mesenteric blood flow and cardiac parameters in end-jejunostomy short bowel patients.

机译:胰高血糖素样肽2对空肠造口术短肠患者肠系膜血流和心脏参数的影响。

获取原文
获取原文并翻译 | 示例
获取外文期刊封面目录资料

摘要

BACKGROUND: Exogenous Glucagon-Like Peptide-2 (GLP-2) treatment improves intestinal wet weight absorption in short bowel syndrome (SBS) patients. In healthy subjects, administration of GLP-2 increases small intestinal blood flow. The aim of the study was to evaluate the effect of GLP-2 on mesenteric blood flow and dynamic changes in cardiac parameters in SBS patients with jejunostomy and varying length of remnant small intestine. METHODS: 8 SBS patients with end-jejunostomy and less than 200 cm small intestine were given GLP-2, 1600 mug subcutaneously (SC), or isotonic saline in a double blinded manner. At 0, 30 and 60 min plasma GLP-2 was measured, and from 0 to 90 min, blood flow in the superior mesenteric artery (SMA) and the celiac artery (CA) was measured using Doppler ultrasound (US), and cardiovascular variables were measured by continuous impedance cardiography and finger plethysmography. RESULTS: Plasma GLP-2 concentrations increased significantly in the GLP-2 group, whereas no changes were seen in the placebo group. Compared to baseline, GLP-2 SC elicited a 19.4% decrease (p<0.01) in the resistance index (RI) and a 97.6% increase in time averaged maximal velocity (TAMV) in the SMA (P<0.01). In the CA there were no significant changes in RI or TAMV in the GLP-2 or placebo group. Blood flow and length of remaining intestine were correlated (RI: y=0.14+4.3, R=0.83, p=0.01 and TAMV: y=1.21+21.3, R=0.63, p=0.09). GLP-2 non significantly increased cardiac output (CO), stroke volume (SV) and significantly increased heart rate (HR) compared to baseline. CONCLUSION: Subcutaneous GLP-2 increased SMA blood flow in end-jejunostomy SBS patients with less than 200 cm of remaining small intestine. The increase in blood flow correlated with the length of remaining intestine, suggesting that the increase is coupled to the metabolic actions of GLP-2 on the gut rather than effects on the vasculature.
机译:背景:外源性胰高血糖素样肽2(GLP-2)治疗可改善短肠综合征(SBS)患者的肠道湿重吸收。在健康受试者中,服用GLP-2可增加小肠血流量。这项研究的目的是评估GLP-2对空肠造口术和残余小肠长度不同的SBS患者肠系膜血流和心脏参数动态变化的影响。方法:对8例SBS空肠造口术和小肠少于200厘米的患者,采用双盲方式给予GLP-2、1600杯皮下注射(SC)或等渗盐水。在0、30和60分钟时测量血浆GLP-2,并在0至90分钟时使用多普勒超声(US)测量肠系膜上动脉(SMA)和腹腔动脉(CA)的血流,并测量心血管变量通过连续阻抗心动图和手指体积描记法测量。结果:GLP-2组血浆GLP-2浓度显着增加,而安慰剂组未见变化。与基线相比,GLP-2 SC引起SMA的阻力指数(RI)降低19.4%(p <0.01),时间平均最大速度(TAMV)升高97.6%(P <0.01)。在CA中,GLP-2或安慰剂组的RI或TAMV没有明显变化。血流量和剩余肠长相关(RI:y = 0.14 + 4.3,R = 0.83,p = 0.01,TAMV:y = 1.21 + 21.3,R = 0.63,p = 0.09)。与基线相比,GLP-2的心输出量(CO),中风量(SV)和心率(HR)没有明显增加。结论:在空肠造口术结束的SBS患者中,皮下GLP-2增加了SMA血流量,剩余小肠少于200 cm。血流量的增加与剩余小肠的长度相关,这表明这种增加与GLP-2对肠道的代谢作用有关,而不是对脉管系统的影响。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号